Cosmo Pharmaceuticals Future Growth
Future criteria checks 4/6
Cosmo Pharmaceuticals is forecast to grow earnings and revenue by 17.2% and 14.2% per annum respectively. EPS is expected to grow by 17.2% per annum. Return on equity is forecast to be 22% in 3 years.
Key information
17.2%
Earnings growth rate
17.2%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | 14.2% |
| Future return on equity | 22.0% |
| Analyst coverage | Low |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 250 | 104 | 181 | 127 | 4 |
| 12/31/2025 | 236 | 96 | 114 | 114 | 5 |
| 12/31/2024 | 266 | 128 | 150 | 149 | 5 |
| 6/30/2024 | 185 | 70 | 98 | 117 | N/A |
| 3/31/2024 | 139 | 32 | 58 | 75 | N/A |
| 12/31/2023 | 93 | -5 | 18 | 34 | N/A |
| 9/30/2023 | 99 | 3 | 21 | 35 | N/A |
| 6/30/2023 | 104 | 11 | 24 | 36 | N/A |
| 3/31/2023 | 103 | 14 | 25 | 35 | N/A |
| 12/31/2022 | 102 | 17 | 26 | 33 | N/A |
| 9/30/2022 | 90 | 26 | 17 | 24 | N/A |
| 6/30/2022 | 78 | 35 | 8 | 16 | N/A |
| 3/31/2022 | 72 | 28 | 6 | 14 | N/A |
| 12/31/2021 | 65 | 22 | 4 | 13 | N/A |
| 9/30/2021 | 64 | 6 | 8 | 16 | N/A |
| 6/30/2021 | 63 | -11 | 12 | 19 | N/A |
| 3/31/2021 | 62 | -9 | 8 | 16 | N/A |
| 12/31/2020 | 61 | -8 | 5 | 13 | N/A |
| 9/30/2020 | 64 | -7 | -1 | 6 | N/A |
| 6/30/2020 | 67 | -7 | -8 | 0 | N/A |
| 3/31/2020 | 65 | -16 | -22 | -9 | N/A |
| 12/31/2019 | 62 | -24 | -36 | -19 | N/A |
| 9/30/2019 | 56 | -28 | -35 | -17 | N/A |
| 6/30/2019 | 50 | -31 | -34 | -15 | N/A |
| 3/31/2019 | 58 | -24 | -27 | -12 | N/A |
| 12/31/2018 | 66 | -18 | -20 | -10 | N/A |
| 9/30/2018 | 69 | -20 | -23 | -10 | N/A |
| 6/30/2018 | 73 | -23 | -26 | -11 | N/A |
| 3/31/2018 | 70 | -28 | N/A | -10 | N/A |
| 12/31/2017 | 68 | -32 | N/A | -9 | N/A |
| 9/30/2017 | 68 | -18 | N/A | -6 | N/A |
| 6/30/2017 | 69 | -4 | N/A | -2 | N/A |
| 3/31/2017 | 69 | 8 | N/A | 10 | N/A |
| 12/31/2016 | 68 | 19 | N/A | 22 | N/A |
| 9/30/2016 | 70 | 18 | N/A | 18 | N/A |
| 6/30/2016 | 72 | 16 | N/A | 14 | N/A |
| 3/31/2016 | 66 | 132 | N/A | -13 | N/A |
| 12/31/2015 | 61 | 248 | N/A | -39 | N/A |
| 9/30/2015 | 60 | 241 | N/A | -13 | N/A |
| 6/30/2015 | 59 | 234 | N/A | 13 | N/A |
| 3/31/2015 | 69 | 154 | N/A | 40 | N/A |
| 12/31/2014 | 80 | 73 | N/A | 66 | N/A |
| 9/30/2014 | 76 | 78 | N/A | 43 | N/A |
| 6/30/2014 | 72 | 82 | N/A | 20 | N/A |
| 3/31/2014 | 65 | 75 | N/A | 14 | N/A |
| 12/31/2013 | 57 | 69 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0RGI's forecast earnings growth (17.2% per year) is above the savings rate (2.1%).
Earnings vs Market: 0RGI's earnings (17.2% per year) are forecast to grow faster than the UK market (14.6% per year).
High Growth Earnings: 0RGI's earnings are forecast to grow, but not significantly.
Revenue vs Market: 0RGI's revenue (14.2% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0RGI's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0RGI's Return on Equity is forecast to be high in 3 years time (22%)